Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Recent innovations in ADC design and innate immune modulation reveal complementary therapeutic strategies for cancer and inflammatory diseases. Novel hydrophilic multivalent linkers enable very high drug-to-antibody ratios and dual-payload ADCs, while modulation of MDAS, TLR7, TLR5, and STING pathways induces p16 + immune subsets that promote disease tolerance. Together, these inventions highlight convergent mechanisms for improving efficacy, resilience, and therapeutic durability.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: